ProfileGDS5678 / 1435382_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 83% 88% 82% 87% 78% 75% 86% 87% 88% 74% 84% 84% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9457682
GSM967853U87-EV human glioblastoma xenograft - Control 26.1671283
GSM967854U87-EV human glioblastoma xenograft - Control 36.8991488
GSM967855U87-EV human glioblastoma xenograft - Control 46.1018182
GSM967856U87-EV human glioblastoma xenograft - Control 56.757887
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2641578
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8262875
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.416486
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6384687
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8740888
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7930574
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2644384
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1506884
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6668880